[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-partum-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-partum-hemorrhage":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,42,76,101,122,143,173,196,218,239,260,281,301,330],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100514376","hemoglobin-testing-in-pregnant-patients-100514376",false,"NCT05977686","Hemoglobin Testing in Pregnant Patients","Point-Of-Care Anemia Testing in Pregnant Patients - A Prospective Observational Study","AnemiaPOC","Inclusion Criteria:\n\n* Pregnant women ages 18-50 years old\n\nExclusion Criteria:\n\n* Patients with hemoglobinopathies (qualitative defects, sickle-cell anemia) and hemoglobin synthesis disorders (quantitative defects such as thalassemia)\n* Patients with peripheral vascular diseases and skin conditions that affect blood vessels in the digit\n* Patients with hyperbilirubinemia",true,"FEMALE","18 Years","50 Years",{"count":22,"type":23},250,"ESTIMATED","OBSERVATIONAL","The project is a prospective observational study aimed to assess and to validate the use of point-of-care hemoglobin testing in pregnancy. Point-of-care hemoglobin testing has the potential to (1) increase access to hemoglobin monitoring in pregnancy in low resource settings, (2) increase availability of hemoglobin monitoring in anemic patients, and (3) provide immediate results for real-time patient counseling and intervention. However, to date, point-of-care hemoglobin testing devices have not yet been studied for use in an ambulatory obstetric population. The Masimo device is a Root Radical 7 Pulse CO-Oximeter, manufactured by Masimo, Inc. This device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value. The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement, and The Rubby is a mobile application based platform that uses a photo of the participants nailbed to estimate hemoglobin values. Participants in this study will be approached at the Obstetrics and Gynecology clinics at George Washington Medical Faculty Associates. Point-of-care hemoglobin measurements will be assessed using the non-invasive Masimo device along with minimally-invasive hemoglobin HemoCue® Hb 801 device and compared to traditional venipuncture hemoglobin testing.",[27,28],"Post Partum Hemorrhage","Anemia of Pregnancy","RECRUITING","2026-04-21",{"date":32,"type":33},"2026-04-23","ACTUAL",{"date":35,"type":33},"2025-12-03",{"date":37,"type":23},"2026-12",{"name":39,"class":40},"Inova Health Care Services","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100590520","phase-2-sublingual-oxytocin-for-the-prevention-of-post-partum-hemorrhage-100590520","NCT06968481","Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage","Phase 2, Open-label, Randomized, Dose Ascending Trial to Evaluate the Efficacy and Safety of Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage Caused by Uterine Atony in Term Pregnant Women With Uncomplicated Vaginal Delivery","Inclusion Criteria:\n\n1. Women willing and able to provide Informed consent.\n2. Women who are able to understand, confirm and give informed consent during an antenatal visit or first stage of labor (cervical dilation \\\u003C6 cm).\n3. Healthy, primiparous or multiparous (2-4 deliveries), term-pregnant female with a gestational age of 37 to 42 weeks (inclusive). Gestational age should be confirmed with an obstetrical ultrasound if available.\n4. Aged between 18 and 40 years (both inclusive).\n5. Confirmed singleton pregnancy.\n6. Based on the Investigator assessment, maternal and fetal conditions are met to expect a vaginal delivery.\n7. For participants in the PK subgroup: women with baseline hemoglobin level ≥11 g\u002FdL.\n\nExclusion Criteria:\n\n1. Women who are unable to provide written Informed consent.\n2. Women undergoing an elective or emergency cesarean section.\n3. Conditions predisposing to uterine atony and PPH (e.g., previous PPH, placenta praevia, multiple gestation, severe pre-eclampsia, polyhydramnios, uterine fibroids, need for induction of labor, bleeding diathesis, sepsis, body mass index \\[BMI\\] ˃ 30 kg\u002Fm2 , macrosomia with estimated fetal weight \\>4500 g, if antenatal ultrasound was performed).\n4. Women with moderate or severe anemia (defined as Hb \\\u003C10 g\u002FdL).\n5. Women who have undergone female genital mutilation.\n6. Known allergies to carbetocin, other oxytocin homologues or excipients in the medicinal products used in the trial.\n7. Oral conditions before administration of sublingual oxytocin such as moderate erythema and edema, severe irritation\u002Finflammation, moderate or severe abrasion.\n8. Conditions predisposing to myocardial ischemia due to pre-existing cardiovascular diseases (such as hypertrophic cardiomyopathy, valvular heart disease and\u002For ischemic heart disease, including vasospasm of the coronary arteries) or known long QT syndrome or related symptoms.\n9. Any clinically significant abnormality following review of medical history, laboratory result and physical examination at screening as judged by the Investigator (e.g., severe anemia, antepartum hemorrhage, mental disorder, history of cervical cancer or history of severe infection of the uterus, religious beliefs prohibiting blood transfusions).\n10. Previous surgery of the cervix or uterus or any other preexisting condition that could interfere with the measurement of uterine contractility.\n11. Current use or use within 30 days before the start of the IMP or reference product of one or more of predefined medications","40 Years",{"count":51,"type":23},330,"INTERVENTIONAL",[54],"PHASE2","An open-label, randomized, single-center, dose ascending trial will be conducted to evaluate the efficacy and safety of sublingual oxytocin for the prevention of post-partum hemorrhage caused by uterine atony in term pregnant women having an uncomplicated vaginal delivery.",[27],[58,59,60,61,62,63,64],"sublingual oxytocin","oxytocin","post-partum hemorrhage","severe post-partum hemorrhage","SPPH","Prevention of post-partum hemorrhage","Efficacy and safety","NOT_YET_RECRUITING","2026-04-20",{"date":32,"type":33},{"date":69,"type":23},"2026-05-30",{"date":71,"type":23},"2026-10-30",{"name":73,"class":74},"Insud Pharma","INDUSTRY",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":83,"targetDuration":4,"studyType":52,"phases":85,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":99,"locationsCount":75},"100541705","comparative-efficacy-of-carbetocin-and-oxytocin-in-parturients-at-risk-of-atonic-postpartum-hemorrhage-undergoing-elective-cesarean-delivery-100541705","NCT06333340","Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery","Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery: a Randomized Controlled Trial","Inclusion criteria - Any one or more of the risk factors for uterine atony:\n\n* Overdistended uterus due to:\n\n  * Polyhydramnios (amniotic fluid index \\>24 cm)\n  * Fetal macrosomia reported on prenatal ultrasound \\>90th centile or \\> 4000 gm\n  * Multiple gestation\n* History of uterine atony\u002FPPH (documented with blood loss of \\>1000 ml, blood transfusion, use surgical methods such as Bakri balloon, B-Lynch sutures, uterine artery ligation or embolization)\n* Obesity with body mass index (BMI) \\>40 kg\u002Fm2\n* Diabetes mellitus on treatment\n* Preeclampsia on treatment\n* Placenta previa\n\nExclusion criteria:\n\n* Valvular heart disease, arrhythmias, or heart failure\n* Placenta accreta spectrum\n* Bleeding disorder\n* Anemia (\\\u003C100 g\u002Fdl)\n* Allergy or sensitivity to oxytocin or carbetocin",{"count":84,"type":23},160,[86],"NA","The goal of this study is to compare 2 medications that are commonly used to prevent excess uterine bleeding (postpartum hemorrhage, or PPH) following cesarean delivery (CD), oxytocin and carbetocin. Most of the trials evaluating the preventative role of oxytocin and carbetocin after CD have focused on patient with low-risk of PPH.\n\nThis trial will focus on patients that are at increased risk of PPH, with risk factors such as: multiple gestation (twins, or more multiples), large baby, polyhydramnios (excess amniotic fluid), history of PPH, body mass index greater than 40, diabetes mellitus, hypertension, and placenta previa.\n\nThe investigators hypothesize that carbetocin would be more effective than an oxytocin regimen in reducing the risk of PPH in patients undergoing CD with any of the biological high-risk factors.",[27],[59,90,91,92],"carbetocin","cesarean delivery","pregnancy","2026-03-31",{"date":95,"type":33},"2026-04-01",{"date":97,"type":33},"2025-01-14",{"date":37,"type":23},{"name":100,"class":40},"Samuel Lunenfeld Research Institute, Mount Sinai Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":109,"targetDuration":4,"studyType":52,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":41},"100467749","phase-2-prevention-of-postpartum-hemorrhage-with-tranexamic-acid-100467749","NCT05370820","Prevention of Postpartum Hemorrhage With Tranexamic Acid","Prevention of Postpartum Hemorrhage: Pharmacokinetics (PK) Abd Pharmacodynamics (PD) of Tranexamic Acid","Optimum OB-TXA","Inclusion Criteria:\n\n* Women who are scheduled to under medically indicated cesarean section at greater than 34+0 weeks gestation or women who are scheduled to undergo an elective cesarean section at 39+0 weeks gestation in accordance with recommendations from the American Congress of Obstetricians and Gynecologists\n* Women who are indicated to have a vaginal delivery at \\> 34+0 weeks gestation.\n* Pregnant women with normal serum creatinine (serum creatinine \\\u003C 0.9) within 2 weeks of estimated\u002Fscheduled delivery\n* Women between the ages of 18 and 50 years old\n* Ability to understand and the willingness to sign a written informed consent form and HIPAA Authorization.\n\nExclusion Criteria:\n\n* active thrombotic or thromboembolic disease\n* a history of arterial or venous thromboembolic event\n* inherited thrombophilia or preexisting conditions that predisposes them to thromboembolic events (i.e. lupus, antiphospholipid syndrome, thrombocytosis or thrombophilic thrombocytopathy)\n* a subarachnoid hemorrhage\n* acquired defective color vision\n* history of seizure disorder\n* known renal dysfunction (serum creatinine = or \\>0.9)\n* multiple gestations (twin or triplet pregnancies)\n* hypersensitivity to Tranexamic acid or anti-fibrinolytic therapy\n* history of liver dysfunction at the discretion of the investigator",{"count":110,"type":23},120,[54],"In part 1 of the study, the investigators conducted a prospective, open-label, dose finding pharmacokinetic (PK) study in 43 pregnant 3rd trimester women scheduled for non-emergent cesarean section.\n\nThe investigators administered three doses of the drug (5 mg\u002Fkg, 10 mg\u002Fkg and 15 mg\u002Fkg) in an escalating fashion by cohort with the lowest dose first. The drug was administered intravenously at the time of umbilical cord clamping for a non-emergent cesarean section. A maximum of 1 g was administered. TXA serum levels at several time points after delivery were assayed to see if they reach the target plasma concentration of 10 ug\u002FmL. A PK model was constructed for determining the optimal TXA dose administered at parturition.\n\nIn part 2 of the study, the investigators aim to compare PKPD endpoints using prophylactic TXA via IV and IM routes administered pre-cord clamp. The investigators will administer 1 g TXA within 10 minutes of skin incision via intravenous infusion (up to n=15), intravenous bolus \\\u003C 2 minutes (up to n=15) and intramuscular injection (up to n=15). The investigators will target women undergoing scheduled cesarean delivery \\> 34 weeks gestation, women undergoing vaginal delivery \\> 34 weeks of gestation and morbidly obese women (BMI\\>=40) undergoing either a vaginal or cesarean delivery. The investigators will use advanced modeling techniques to determine time to achieve PKPD targets and duration remaining at those targets. The goal will be to determine how the optimal dose may vary if route of administration is modified. The investigators plan to enroll 45 patients in addition to the 43 that were enrolled during part 1. Our goal is to 30 participants, but the investigators will enroll 45 to account for lost to follow-up. The investigators also aim to enroll 30 patients undergoing vaginal delivery and 30 morbidly obese women (BMI \\>= 40) undergoing either a vaginal or cesarean delivery but the investigators will enroll 45 patients for each of these groups to account for loss to follow up. In addition, the investigators will enroll 30 pregnant patients receiving no medication acting as the control group, but the investigators will enroll 45 to account for loss to follow up.",[27],"2026-03-23",{"date":116,"type":33},"2026-03-27",{"date":118,"type":33},"2022-12-28",{"date":120,"type":23},"2027-06-01",{"name":39,"class":40},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":52,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100617426","prophylactic-regimen-of-intravenous-oxytocin-intravenous-tranexamic-acid-and-intramuscular-ergot-derivative-for-primary-prevention-of-postpartum-hemorrhage-in-intrapartum-cesarean-section-versus-intravenous-carbetocin-alone-100617426","NCT07318467","Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone","Inclusion Criteria:\n\n* Women undergoing C-Sections.\n* Women between the ages of 18 and 45 years.\n* Singleton pregnancy.\n* Gestational age is equal to or more than 36 weeks.\n* No known coagulopathy or bleeding disorders.\n* No known hypersensitivity or allergy to drugs used in the study.\n* Normal obstetric ultrasonography with no fetal abnormalities.\n\nExclusion Criteria:\n\n* Hemodynamically unstable or immobile patients.\n* Multifetal pregnancy.\n* Patients who are receiving prophylactic or therapeutic anticoagulation.\n* Known comorbidities and contraindications to the use of Ergot derivatives or Carbetocin such as hypertension or cardiovascular disorders.\n* Placenta previa and\u002For Placenta accreta spectrum.\n* History of thromboembolism.\n* Preeclampsia or eclampsia.\n* Any additional measurements needed to control or stop excessive bleeding intraoperatively such as uterine artery ligation or use of sterile gelatin absorbable foam.","45 Years",{"count":130,"type":23},80,[86],"While Carbetocin is effective in reducing PPH, the combination of oxytocin, Tranexamic acid, and Ergot derivatives may offer additional benefits in high-risk populations. We hypothesize that the combination regimen will reduce PPH incidence and severity compared to Carbetocin alone and may be more cost effective",[27],"2025-12-20",{"date":136,"type":33},"2026-01-06",{"date":138,"type":23},"2026-01-01",{"date":140,"type":23},"2026-06-30",{"name":142,"class":40},"Cairo University",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":150,"targetDuration":4,"studyType":52,"phases":152,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":41},"100476785","phase-2-oxytocin-pharmacokinetics-and-pharmacodynamics-100476785","NCT05488457","Oxytocin Pharmacokinetics and Pharmacodynamics","Pharmacokinetics and Pharmacodynamics of Oxytocin in Cesarean Delivery","Inclusion Criteria\n\n* 18-50 years old\n* intrauterine pregnancy\n* term (\\>39 weeks gestation or 37-39 weeks gestation with fetal or maternal medical indication for delivery) pregnancy\n* non-emergent (scheduled or unscheduled) cesarean delivery\n\nExclusion Criteria:\n\n* allergy or contraindication to oxytocin\n* inability to provide informed consent",{"count":151,"type":23},100,[54],"Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S. and rates are increasing. This two-part study will measure the action of oxytocin at cesarean delivery. The first part will measure the pharmacokinetics of a single intravenous (IV) dose of deuterium-labeled oxytocin. The second part will measure the pharmacodynamics of all plasma oxytocin to see how concentrations correspond to the contractile effect on the uterus.\n\nAfter delivery of the fetus, study subjects will receive a bolus of IV deuterated oxytocin followed by an unlabeled oxytocin infusion. Venous blood samples drawn at multiple time points (within 1 hour after delivery) will be analyzed for plasma concentrations of labeled and unlabeled (endogenous + exogenous infused) oxytocin over time. Plasma concentrations will be compared with 0-10 uterine tone scores measuring uterine contraction strength, to describe the concentration-effect relationship.\n\nThe goal of this study is to define both the pharmacokinetics and pharmacodynamics of oxytocin in parturients to help identify the cause(s) of failed first-line oxytocin therapy.",[27,155,156],"Cesarean Section Complications","Blood Loss",[158,159,160,161,162,163],"Oxytocin","pharmacokinetics and Pharmacodynamics","Uterine Tone","Postpartum","Elective C-Section","Parturients","2025-10-01",{"date":166,"type":33},"2025-10-03",{"date":168,"type":33},"2025-01-01",{"date":170,"type":23},"2027-12-31",{"name":172,"class":40},"University of Chicago",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":52,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":192,"leadSponsor":194,"locationsCount":75},"100555535","a-pragmatic-randomized-controlled-trial-to-predict-postpartum-hemorrhage-100555535","NCT06513351","A Pragmatic Randomized Controlled Trial to Predict Postpartum Hemorrhage","Logistic Regression Prediction Model vs. Standard of Care for Prediction of Postpartum Hemorrhage - A Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n* All vaginal and cesarean deliveries occurring at Vanderbilt University Medical Center\n\nExclusion Criteria:\n\n* All patients will be randomized at the time of admission to the obstetric service. Patients who are discharged prior to delivery will be excluded from subsequent analysis. Any patients with a pre-delivery planned hysterectomy (for placenta increta or percreta) will be excluded from the treatment algorithm and primary analysis.",{"count":181,"type":23},10000,[86],"This research project aims to enhance the safety of childbirth by using advanced computer models to predict the risk of postpartum hemorrhage (PPH).\n\nPPH is a significant concern for mothers during and after delivery. Current risk assessment tools are basic and do not adapt to changing conditions. This study will investigate whether a new and recently validated model for predicting PPH, combined with a provider-facing Best Practice Advisory (BPA) regarding currently recommended strategies triggered by an increased predicted risk, can improve perinatal outcomes.\n\nThis study will compare the current category based risk assessment tool with a new, enhanced prediction model which calculates risk based on 21 factors, automatically updates as new information becomes available during labor and, if elevated, provides a provider-facing Best Practice Advisory (BPA) recommending consideration of strategies that are institutionally agreed to represent high-quality practice.\n\nInvestigators hypothesize that the enhanced care approach will result in improved perinatal outcomes.\n\nThe goal of the study is to improve the wellbeing of mothers during childbirth by harnessing the power of modern technology and data analysis.",[27],[27,186,187,188],"Cesarean Section","Vaginal Birth","Risk Prediction","2025-09-29",{"date":164,"type":33},{"date":168,"type":33},{"date":193,"type":23},"2027-07",{"name":195,"class":40},"Holly Ende",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":202,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":41},"100543138","evaluating-placental-thickness-and-thickness-of-uterine-muscle-at-placenta-attachment-in-prediction-of-postpartum-blood-loss-in-placenta-accreta-100543138","NCT06351969","Evaluating Placental Thickness and Thickness of Uterine Muscle at Placenta Attachment in Prediction of Postpartum Blood Loss in Placenta Accreta","Inclusion Criteria:\n\n* Term pregnancy (37 wk gastation and more )\n* Single viable fetus\n\nExclusion Criteria:\n\n* Severe hematological disorders that could cause abnormal coagulation\n* Previous history of PPH\n* twins\n* Preterm labour\n* IUFD",{"count":203,"type":23},150,"Aim of the Work is To determine the significance of the placental thickness and the thickness of the uterine muscle layer at placental attachment in the prediction of postpartum hemorrhage in cases of placenta previa accreta and to evaluate both of them as as parameters for identifying high-risk patients.",[27],[27,207,208,209],"placental thickness","cesarean section","vaginal delivery","2025-06-03",{"date":212,"type":33},"2025-06-06",{"date":214,"type":23},"2025-06",{"date":37,"type":23},{"name":217,"class":40},"Benha University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":128,"enrollmentInfo":224,"targetDuration":4,"studyType":52,"phases":226,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":75},"100593154","phase-1-role-of-prophylactic-tranexamic-acid-in-prevention-of-post-partum-hemorrhage-in-ellscs-100593154","NCT07002749","ROLE OF PROPHYLACTIC TRANEXAMIC ACID IN PREVENTION OF POST-PARTUM HEMORRHAGE IN ELLSCS","Inclusion Criteria:\n\n* Pregnant women with singleton pregnancy and low risk for PPH admitted for ELLSCS\n\nExclusion Criteria:\n\nWomen with medical disorder or complex pregnancy.\n\n* Women with history of PPH.\n* Women with bleeding disorder.\n* Abnormal placentation (MAP, placenta previa)\n* Multiple pregnancy.",{"count":225,"type":23},104,[227],"PHASE1","IN THIS STUDY WOMEN UNDER GOING ELLSCS WOULD BE DIVIDED INTO TWO GROUPS , ONE GROUP WOULD BE GIVEN TRANEXAMIC ACID WHILE THE OTHER WOULD BE GETTING PLACEBO PROPHYLACTICALLY TO SEE THE EFFECT OF TRANEXAMIC ACID IN PREVENTING PPH.\n\nTHIS IS A RANDOMIZED CONTROLLED TRIAL. THE SAMPLING TECHNIQUE WOULD BE NON-PROBABILITY TECHNIQUE RANDOMIZATION WOULD BE DONE VIA BALLOTING METHOD.",[27],"2025-05-25",{"date":232,"type":33},"2025-06-04",{"date":234,"type":23},"2025-06-01",{"date":236,"type":23},"2025-12-31",{"name":238,"class":40},"Patel Hospital, Pakistan",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":17,"sex":18,"minAge":245,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":75},"100585105","postpartum-ultrasound-evaluation-to-assess-risk-of-hemorrhage-100585105","NCT06898034","Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage","Inclusion Criteria:\n\n* Currently pregnant and planning to deliver at Endeavor Health \\>37 weeks gestational age\n* English speaking\n* Labor \\\u003C6cm dilated at time of consent without epidural\n* Labor \\\u003C8cm dilated at time of consent with epidural\n\nExclusion Criteria:\n\n* Preterm delivery\n* Non-English speaking\n* Any conditions that impairs potential participants decision making","17 Years",{"count":247,"type":23},1725,"Up to 5% of patients in the United States have a postpartum hemorrhage. \"Postpartum hemorrhage\" means excessive bleeding after delivery. The majority of these bleeds occur immediately with delivery.\n\nThe current study focuses on hemorrhages that occur in the \"medium-term\" (1.5-24 hours after delivery). Investigators are examining whether ultrasound exams performed at the beginning of this period 1.5 to 2 hours after birth can identify markers that predict a medium-term bleed. Data collected for this study will include medical and obstetrical history, details about the course and outcomes of patients' labor and delivery, and particulars about postpartum bleeding. This information will be collected through the end of the patients' delivery admission and will allow correlation with the results of the ultrasound exam. If patients are re-admitted to the hospital after the delivery discharge, investigators may also collect relevant information about those admissions up to 6 weeks postpartum.\n\nAll patients after term delivery (≥ 37 weeks' gestation) will be eligible to participate. Patients will be approached to provide consent for participation as early as feasible during a prenatal visit (≥ 36 weeks' gestation) or during the delivery admission. No subjects will be consented while in significant pain, \\>6cm dilated without an epidural, or \\>8cm dilatated with an epidural.",[250,27],"Pregnancy Related","2025-03-20",{"date":253,"type":33},"2025-03-27",{"date":255,"type":33},"2025-03-10",{"date":257,"type":23},"2027-03",{"name":259,"class":40},"Endeavor Health",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":128,"enrollmentInfo":267,"targetDuration":4,"studyType":52,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":75},"100562527","prophylactic-tranexamic-acid-to-reduce-blood-loss-during-caesarean-delivery-100562527","NCT06604325","Prophylactic Tranexamic Acid To Reduce Blood Loss During Caesarean Delivery.","Prophylactic Role Of Tranexamic Acid To Reduce Blood Loss During Caesarean Delivery : A Prospective Study.","Inclusion Criteria:\n\n1. The women undergoing cesarean delivery (both elective and emergency) during the study period.\n2. Willing to participate in the study after understanding the concept.\n\nExclusion Criteria:\n\n1. Critically ill patient.\n2. Not willing to give consent to participate in the study\n3. Cases diagnosed with a ruptured uterus or undergoing caesarian hysterectomy during operation.",{"count":268,"type":23},300,[86],"Postpartum hemorrhage continues to be the leading cause of maternal morbidity and mortality. Globally, it is responsible for 25% of all pregnancy-related deaths. PPH is unpredictable and may occur in the absence of risk factors. Tranexamic acid is an antifibrinolytic proven to reduce blood loss and transfusion requirements for various surgeries. This study aims to explore the effectiveness of tranexamic acid as an adjunct to other uterotonics before the Caesarian Section.",[27],"2024-10-22",{"date":274,"type":33},"2024-10-24",{"date":276,"type":33},"2024-10-01",{"date":278,"type":23},"2025-03-30",{"name":280,"class":40},"Aligarh Muslim University",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":18,"minAge":288,"maxAge":49,"enrollmentInfo":289,"targetDuration":4,"studyType":52,"phases":290,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":299,"leadSponsor":300,"locationsCount":75},"100516886","phase-3-comparing-intramyometrial-tranexamic-acid-and-oxytocin-for-blood-loss-in-cesarean-section-100516886","NCT06010368","Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section","The Effect of Intramyometrial Tranexamic Acid Versus Intramyometrial Oxytocin in Reducing Blood Loss During and After Elective Cesarean Section in Term Primigravida: A Double-blinded, Randomized, Comparative-placebo Trial","nclusion Criteria:\n\n* Women booked for a primary elective cesarean section, not in active labor\n* Aged between 20-40 years.\n* BMI 18.5-29.9 kg\u002F m2 pre-pregnancy weight\n* Term pregnancies (Early term: between 37 weeks, 0 days and 38 weeks, 6 days. Full term: between 39 weeks, 0 days and 40 weeks, 6 days. Late term: between 41 weeks, 0 days and 41 weeks, 6 days).\n* Singleton pregnancies.\n* Indication of elective cesarean section (Malpresentation, Malposition, Cephalopelvic disproportion, active herpes)\n* Fetal macrosomia (Macrosomia is defined as birth-weight over 4,000 g irrespective of gestational age)\n* Certain congenital fetal malformation and skeletal disorders (Several congenital anomalies are controversial indications for cesarean delivery; these include fetal neural tube defects (to avoid sac rupture), particularly defects that are larger than 5-6 cm in diameter as anterior cystic hygroma vascular sacrococcygeal teratoma, giant omphalocele and hydrocephalus with an enlarged biparietal diameter, and some skeletal dysplasia such as type III osteogenesis imperfecta. (Hamrick et al., 2008)\n\nExclusion Criteria:\n\n* Placenta previa.\n* Maternal hypertension and Preeclampsia.\n* Diabetes mellitus.\n* Severe medical disorder (renal or hepatic).\n* Multiple Fibroid uterus.\n* Multiple pregnancies.\n* Polyhydramnios.\n* Previous uterine surgery as myomectomy.\n* Contraindication to spinal anesthesia.\n* Blood coagulopathy and bleeding disorder.\n* Marked maternal anemia (Preoperative hemoglobin \\\u003C9 gm\u002Fdl).\n* Contraindications to TXA or oxytocin therapy (e.g. allergy)","20 Years",{"count":203,"type":23},[291],"PHASE3","Cesarean section is the most prevalent operation among women globally, 10-15% (1, 2). Recent research has shown Egypt to be the third-largest country globally, with an estimated 52% cesarean sections (3). However, the cesarean section has many serious complications, including the primary postpartum hemorrhage (PPH) (4). During labor, the average blood loss is about 300 to 400 ml. Bleeding postpartum is known as losing over five hundred milliliter of blood following a vaginal birth and losing over one thousand milliliter after the cesarean section (5). The prime cause of maternal death rate is postpartum bleeding, predominately in poor countries, and the estimated mortality number due to postpartum bleeding is one hundred thousand per year (6). Therefore, it is essential to reduce bleeding during and after CS to diminish maternal mortality and morbidity (7). The most successful technique for decreasing PPH is the active third stage labor management, requiring prophylactic uterotonic drugs like oxytocin, ergometrine malate, prostaglandins (E1, E2, and F2α), and combinations of them, or hemostatic agent as tranexamic acid (Kapron) and Etamsylate (Dicynon) (8, 9).",[155,294,158,27],"Tranexamic Acid","2024-09-02",{"date":297,"type":33},"2024-09-05",{"date":276,"type":23},{"date":138,"type":23},{"name":142,"class":40},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":52,"phases":311,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":75},"100560498","evaluation-of-maternal--newborn-health-simulation-lab-centers-of-excellence-in-nepal-100560498","NCT06577922","Evaluation of Maternal & Newborn Health Simulation Lab Centers of Excellence in Nepal","Evaluation of Maternal & Newborn Health Simulation Lab Centers of Excellence in Seven Referral Hospitals of Nepal","SLAB","Inclusion Criteria:\n\n* All women who have recently delivered in the study hospital via vaginal delivery\n* Newborn delivered at the same hospital with gestational age ≥ 37 weeks, birth weight ≥2500 gm, and a fetal heart sound present at the time of admission\n* Maternal and Newborn Health staff working in selected hospitals for at least 3 months\n\nExclusion Criteria:\n\n* Women with Postpartum Hemorrhage (PPH) referred from other hospital, babies born outside of study hospital, and newborns with congenital abnormalities will be excluded.",{"count":310,"type":23},1464,[86],"Postpartum hemorrhage and birth asphyxia are the leading causes of maternal and neonatal mortalities worldwide. Prevention and adequate treatment are, therefore crucial. While Nepal has made significant improvements in maternal and neonatal health, these efforts are insufficient to achieve the Sustainable Development Goal 3. Several studies have revealed critical gaps in the knowledge and clinical skills of maternal and neonatal health (MNH) providers in Nepal, likely due to limited clinical experience and practical exposure. Therefore, One Heart Worldwide is implementing the 'Maternal and Newborn Health Simulation Lab Centers of Excellence' project in 7 referral hospitals of Nepal wherein in simulation labs will be established and simulation-based training will be provided to hospital staff with a focus on essential care of labor and birth, bleeding after birth, and helping babies breathe modules. This implementation study will evaluate the project implementation and effectiveness using a REAIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework. A mixed-methods approach will be used to evaluate each component of RE-AIM using a quasi-experimental pre-test and post-test design. The pre-test data collection will be of 6 months' duration. During this phase, the investigators will collect daily data on maternal and neonatal health outcomes (Post-partum hemorrhage (PPH) incidence, proportion of newborns with APGAR score\\<7 at 5 minutes' assessment, and rate of maternal blood transfusion after PPH), and also assess the skills assessment scores of the MNH service providers. After the completion of pre-test data collection, training will be provided to MNH service providers of the hospital in the established simulation labs. The daily MNH routine data collection will continue during project implementation phase, and till six months after the training MNH service providers of the hospitals. In addition to the assessments done in the pre-test, the investigators will also assess the reach, implementation status, challenges, utilization, and maintenance of established simulation labs. The post-test assessment of skills of MNH service providers will be conducted six months after the completion of the in-hospital trainings. Written informed consent will be obtained from the study participants. For the quantitative data, descriptive and inferential statistical methods will be used for data analysis. Qualitative data will be analyzed using thematic analysis supported by NVIVO 12 software.",[27,314,315],"Asphyxia; Fetal","Maternal-Fetal Relations",[317,318,319,320],"Simulation","Simulation based education","Maternal health","Neonatal health","2024-08-29",{"date":323,"type":33},"2024-09-03",{"date":325,"type":33},"2024-05-01",{"date":327,"type":23},"2026-07-31",{"name":329,"class":40},"One Heart Worldwide",{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":17,"sex":18,"minAge":288,"maxAge":128,"enrollmentInfo":336,"targetDuration":4,"studyType":52,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":4},"100559128","standard-oxytocin-versus-high-dose-oxytocin-to-control-postpartum-hemorrhage-in-high-risk-pregnancy-during-elective-cesarean-section-100559128","NCT06560099","Standard Oxytocin Versus High Dose Oxytocin to Control Postpartum Hemorrhage in High Risk Pregnancy During Elective Cesarean Section","Inclusion Criteria:\n\n* \\- Medical disorders ie: Hypertensive diseases with pregnancy - Diabetes Mellitus - Collagen diseases - Coagulopathies - Cardiac diseases - Anemia\n* History of postpartum hemorrhage\n* Placental disorders ie: placenta previa\n* Infertility and ICSI\n* High Parity\n* History of Endometriosis\n* Fetal disorders (IUGR, IUFD, Preterm, Congenital anomalies, oligohydramnios or polyhydramnios, macrosomia)\n* Preterm labor on uterine relaxants\n* Twins pregnancy\n* Patients on antiplatelets and anticoagulants\n* Uneventful antenatal care\n\nExclusion Criteria:\n\n* \\- Oxytocin Allergy\n* Normal uncomplicated pregnancy\n* Emergency cesarean section\n* Exhausted uterus due to trial of normal labor\n* Couvelaire uterus",{"count":337,"type":23},39,[86],"Controlling hemorrhage during and after a cesarean section reduces significantly maternal mortality and morbidity and the present study is important for detection of the effectiveness of routinely increasing the oxytocin dose instead of using the standard dose only in preventing postpartum hemorrhage and additional use of uterotonics in the first 24 hours after cesarean section for high risk pregnancy.",[27],"2024-08-15",{"date":343,"type":33},"2024-08-19",{"date":345,"type":23},"2024-08-25",{"date":347,"type":23},"2025-04-25",{"name":349,"class":40},"Ain Shams University"]